



## George W. Sledge Jr., M.D.

Professor of Medicine (Oncology) at the Stanford University Medical Center

Medicine - Oncology

 NIH Biosketch available Online

### CLINICAL OFFICES

- **Stanford Womens Cancer Center**

900 Blake Wilbur Dr

1st Fl MC 5854

Palo Alto, CA 94304

**Tel** (650) 498-6004

**Fax** (650) 498-7237

### ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Maria Carrasco - Executive Assistant

**Email** [mcarrasco84@stanford.edu](mailto:mcarrasco84@stanford.edu)

**Tel** 650-724-4397

### Bio

---

### CLINICAL FOCUS

- Cancer
- Cancer > Breast Cancer
- Medical Oncology

### ACADEMIC APPOINTMENTS

- Professor - Med Center Line, Medicine - Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute

### ADMINISTRATIVE APPOINTMENTS

- Professor, and Chief, Division of Oncology, Stanford University Medical Center, (2013- present)

### HONORS AND AWARDS

- Ballve-Lantero Chair (Endowed Chair), Ballve-Lantero (1996)
- Listed in "America's Top Doctors", Castle Connolly (2001-2012)
- Komen Brinker Award for Scientific Distinction, Susan G. Komen Breast Cancer Foundation (2006)
- Jill Rose Award, Breast Cancer Foundation (2007)
- William L. McGuire Award, San Antonio Breast Cancer Symposium (2010)
- Health Care Hero award, Indianapolis Business Journal (2011)
- APEX Award for Publication Excellence in the category of "Regular Departments & Columns", Oncology Times (2012)
- Chair, Breast Committee, Eastern Cooperative Oncology Group (ECOG) (2002-2010)
- Editor-In-Chief, Clinical Breast Cancer (1999-present)
- President, American Society of Clinical Oncology, American Society of Clinical Oncology (ASCO) (2010-2011)

- HOPE Funds for Cancer Research 2013 Award of Excellence for Medicine, HOPE Funds, Cancer Research (April 28, 2013)

## PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (1983)
- Fellowship: The University of Texas at San Antonio (1983) TX
- Board Certification: Internal Medicine, American Board of Internal Medicine (1980)
- Residency: St Louis University Hospital (1980) MO
- Medical Education: Tulane University School of Medicine (1977) LA

## Publications

---

### PUBLICATIONS

- **Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review** *JNCI Cancer Spectrum*  
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., Kurian, A. W.  
2018; 2 (4)
- **Curing Metastatic Breast Cancer.** *Journal of oncology practice / American Society of Clinical Oncology*  
Sledge, G. W.  
2016; 12 (1): 6-10
- **A Call for Viewpoints.** *JAMA oncology*  
Sledge, G. W., Disis, M. L.  
2015; 1 (4): 432-?
- **Targeted Therapy for Cancer in the Genomic Era.** *Cancer journal*  
Afghahi, A., Sledge, G. W.  
2015; 21 (4): 294-298
- **"Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.** *Clinical cancer research*  
Sledge, G. W., Pegram, M. D.  
2015; 21 (12): 2663-2665
- **Everything old is neu again: cellular senescence in HER2-positive breast cancer.** *Journal of the National Cancer Institute*  
Sledge, G. W., Pegram, M. D.  
2015; 107 (5)
- **Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.** *Journal of clinical oncology*  
Perez, E. A., Thompson, E. A., Ballman, K. V., Anderson, S. K., Asmann, Y. W., Kalari, K. R., Eckel-Passow, J. E., Dueck, A. C., Tenner, K. S., Jen, J., Fan, J., Geiger, X. J., McCullough, et al  
2015; 33 (7): 701-708
- **Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial** *JOURNAL OF CLINICAL ONCOLOGY*  
Perez, E. A., Thompson, E. A., Ballman, K. V., Anderson, S. K., Asmann, Y. W., Kalari, K. R., Eckel-Passow, J. E., Dueck, A. C., Tenner, K. S., Jen, J., Fan, J., Geiger, X. J., McCullough, et al  
2015; 33 (7)
- **Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients** *JOURNAL OF NEURO-ONCOLOGY*  
Duchnowska, R., Jassem, J., Goswami, C. P., Dundar, M., Goekmen-Polar, Y., Li, L., Woditschka, S., Biernat, W., Sosinska-Mielcarek, K., Czartoryska-Arlukowicz, B., Radecka, B., Tomasevic, Z., Stepniak, et al  
2015; 122 (1): 205-216
- **The future of breast cancer systemic therapy: the next 10 years.** *Journal of molecular medicine (Berlin, Germany)*  
Telli, M. L., Sledge, G. W.  
2015; 93 (2): 119-125

- **Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.** *Journal of clinical oncology*  
Stearns, V., Chapman, J. W., Ma, C. X., Ellis, M. J., Ingle, J. N., Pritchard, K. I., Budd, G. T., Rabaglio, M., Sledge, G. W., Le Maitre, A., Kundapur, J., Liedke, P. E., Shepherd, et al  
2015; 33 (3): 265-271
- **Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial** *JOURNAL OF CLINICAL ONCOLOGY*  
Stearns, V., Chapman, J. W., Ma, C. X., Ellis, M. J., Ingle, J. N., Pritchard, K. I., Budd, G. T., Rabaglio, M., Sledge, G. W., Le Maitre, A., Kundapur, J., Liedke, P. E., Shepherd, et al  
2015; 33 (3): 265-U163
- **Anti-vascular endothelial growth factor therapy in breast cancer: game over?** *Journal of clinical oncology*  
Sledge, G. W.  
2015; 33 (2): 133-135
- **Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831** *JOURNAL OF CLINICAL ONCOLOGY*  
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Sledge, G., Geyer, C. E., Martino, S., Rastogi, P., Gralow, J., Swain, S. M., Winer, E. P., Colon-Otero, G., Davidson, et al  
2014; 32 (33): 3744-?
- **Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.** *Journal of clinical oncology*  
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Sledge, G., Geyer, C. E., Martino, S., Rastogi, P., Gralow, J., Swain, S. M., Winer, E. P., Colon-Otero, G., Davidson, et al  
2014; 32 (33): 3744-3752
- **Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.** *Nature reviews. Clinical oncology*  
Neal, J. W., Sledge, G. W.  
2014; 11 (11): 627-628
- **Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100** *BRITISH JOURNAL OF CANCER*  
Schneider, B. P., Li, L., Shen, F., Miller, K. D., Radovich, M., O'Neill, A., Gray, R. J., Lane, D., Flockhart, D. A., Jiang, G., Wang, Z., Lai, D., Koller, et al  
2014; 111 (6): 1241-1248
- **Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.** *British journal of cancer*  
Schneider, B. P., Li, L., Shen, F., Miller, K. D., Radovich, M., O'Neill, A., Gray, R. J., Lane, D., Flockhart, D. A., Jiang, G., Wang, Z., Lai, D., Koller, et al  
2014; 111 (6): 1241-1248
- **Improving the quality of cancer care in America through health information technology.** *Journal of the American Medical Informatics Association*  
Feeley, T. W., Sledge, G. W., Levit, L., Ganz, P. A.  
2014; 21 (5): 772-775
- **Heterogeneity and Cancer** *ONCOLOGY-NEW YORK*  
Allison, K. H., Sledge, G. W.  
2014; 28 (9): 772-778
- **Past, Present, and Future Challenges in Breast Cancer Treatment** *JOURNAL OF CLINICAL ONCOLOGY*  
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., Wolff, A. C.  
2014; 32 (19): 1979-1986
- **Past, present, and future challenges in breast cancer treatment.** *Journal of clinical oncology*  
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., Wolff, A. C.  
2014; 32 (19): 1979-1986
- **DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer.** *Journal of the National Cancer Institute*  
Woditschka, S., Evans, L., Duchnowska, R., Reed, L. T., Palmieri, D., Qian, Y., Badve, S., Sledge, G., Gril, B., Aladjem, M. I., Fu, H., Flores, N. M., Gökmen-Polar, et al  
2014; 106 (7)

- **Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103** *BREAST CANCER RESEARCH AND TREATMENT*  
Ruddy, K. J., O'Neill, A., Miller, K. D., Schneider, B. P., Baker, E., Sparano, J. A., Dang, C., Northfelt, D. W., Sledge, G. W., Partridge, A. H.  
2014; 144 (3): 591-597
- **Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing** *BREAST CANCER RESEARCH AND TREATMENT*  
Radovich, M., Clare, S. E., Atale, R., Pardo, I., Hancock, B. A., Solzak, J. P., Kassem, N., Mathieson, T., Storniolo, A. M., Rufenbarger, C., Lillemoe, H. A., Blosser, R. J., Choi, et al  
2014; 143 (1): 57-68
- **Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer** *JOURNAL OF CANCER*  
Goekmen-Polar, Y., Goswami, C. P., Toroni, R. A., Sanders, K. L., Mehta, R., Sirimalle, U., Tanasa, B., Shen, C., Li, L., Ivan, M., Badve, S., Sledge, G. W.  
2014; 5 (8): 633-645
- **ASCO's approach to a learning health care system in oncology.** *Journal of oncology practice / American Society of Clinical Oncology*  
Sledge, G. W., Hudis, C. A., Swain, S. M., Yu, P. M., Mann, J. T., Hauser, R. S., Lichter, A. S.  
2013; 9 (3): 145-148